Next Article in Journal
Emerging Contact-Killing Antibacterial Strategies for Developing Anti-Biofilm Dental Polymeric Restorative Materials
Previous Article in Journal
Dynamic Properties of Heart Fragments from Different Regions and Their Synchronization
 
 
Review

The Platelet Concentrates Therapy: From the Biased Past to the Anticipated Future

1
Division of Oral Bioengineering, Institute of Medicine and Dentistry, Niigata University, Niigata 950-0000, Japan
2
Department of Prosthodontics, Faculty of Dentistry, International Sudan University, Khartoum 79371, Sudan
3
Department of Oral Surgery, Dentistry School, Fluminense Federal University, Rio de Janeiro 05407-002, Brazil
*
Author to whom correspondence should be addressed.
Bioengineering 2020, 7(3), 82; https://doi.org/10.3390/bioengineering7030082
Received: 5 July 2020 / Revised: 25 July 2020 / Accepted: 28 July 2020 / Published: 30 July 2020
The ultimate goal of research on platelet concentrates (PCs) is to develop a more predictable PC therapy. Because platelet-rich plasma (PRP), a representative PC, was identified as a possible therapeutic agent for bone augmentation in the field of oral surgery, PRP and its derivative, platelet-rich fibrin (PRF), have been increasingly applied in a regenerative medicine. However, a rise in the rate of recurrence (e.g., in tendon and ligament injuries) and adverse (or nonsignificant) clinical outcomes associated with PC therapy have raised fundamental questions regarding the validity of the therapy. Thus, rigorous evidence obtained from large, high-quality randomized controlled trials must be presented to the concerned regulatory authorities of individual countries or regions. For the approval of the regulatory authorities, clinicians and research investigators should understand the real nature of PCs and PC therapy (i.e., adjuvant therapy), standardize protocols of preparation (e.g., choice of centrifuges and tubes) and clinical application (e.g., evaluation of recipient conditions), design bias-minimized randomized clinical trials, and recognize superfluous brand competitions that delay sound progress. In this review, we retrospect the recent past of PC research, reconfirm our ultimate goals, and discuss what will need to be done in future. View Full-Text
Keywords: platelet-rich plasma (PRP); platelet-rich fibrin (PRF); platelet concentrates; bone regeneration; randomized controlled trial; standardization; quality assurance platelet-rich plasma (PRP); platelet-rich fibrin (PRF); platelet concentrates; bone regeneration; randomized controlled trial; standardization; quality assurance
Show Figures

Figure 1

MDPI and ACS Style

Kawase, T.; Mubarak, S.; Mourão, C.F. The Platelet Concentrates Therapy: From the Biased Past to the Anticipated Future. Bioengineering 2020, 7, 82. https://doi.org/10.3390/bioengineering7030082

AMA Style

Kawase T, Mubarak S, Mourão CF. The Platelet Concentrates Therapy: From the Biased Past to the Anticipated Future. Bioengineering. 2020; 7(3):82. https://doi.org/10.3390/bioengineering7030082

Chicago/Turabian Style

Kawase, Tomoyuki, Suliman Mubarak, and Carlos Fernando Mourão. 2020. "The Platelet Concentrates Therapy: From the Biased Past to the Anticipated Future" Bioengineering 7, no. 3: 82. https://doi.org/10.3390/bioengineering7030082

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop